Acute Pain News and Research RSS Feed - Acute Pain News and Research

Protein Sciences releases Flublok influenza vaccine for the 2014/2015 season

Protein Sciences releases Flublok influenza vaccine for the 2014/2015 season

Protein Sciences Corporation, manufacturer of the revolutionary Flublok influenza vaccine, announced today that doses of the vaccine have been released and are now available for shipment. [More]
AcelRx plans for resubmission of Zalviso NDA

AcelRx plans for resubmission of Zalviso NDA

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today provided an update on the plans for the resubmission of the Company's New Drug Application (NDA) for Zalviso (sufentanil sublingual tablet system). [More]
Studies support clinical use of antidepressants for treatment of postoperative pain

Studies support clinical use of antidepressants for treatment of postoperative pain

Antidepressants are known to provide effective pain relief for various chronic pain conditions; however, the jury is still out on their use in treating the millions of patients who suffer from acute or chronic pain following surgery. [More]
Regional anesthesia technique allows majority of patients to go home within hours of surgery

Regional anesthesia technique allows majority of patients to go home within hours of surgery

A recent study of an ultrasound-guided regional anesthesia technique, called femoral nerve block, shows that it leads to less opioid use and allows the majority of patients to go home within hours of surgery. [More]
FDA issues Complete Response Letter for AcelRx's Zalviso NDA

FDA issues Complete Response Letter for AcelRx's Zalviso NDA

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Company's new drug application (NDA) for Zalviso (sufentanil sublingual tablet system). [More]
Phase 2 dose-ranging study of AYX1 for prevention of post-surgical pain

Phase 2 dose-ranging study of AYX1 for prevention of post-surgical pain

Adynxx, developer of a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that the first patient was dosed in ADYX-003, a Phase 2 dose-ranging study of AYX1, an investigational drug candidate for the prevention of post-surgical pain. [More]
Grunenthal Group submits Marketing Authorization Application to EMA for ZALVISO

Grunenthal Group submits Marketing Authorization Application to EMA for ZALVISO

AcelRx Pharmaceuticals, Inc. and Grunenthal Group announced today that Grunenthal has submitted a Marketing Authorization Application (MAA) to the European Medicines Authority for ZALVISO for the management of moderate to severe acute pain in adult patients in a medically supervised environment. [More]
Trevena's Phase 1b data for TRV130 published in the journal Pain

Trevena's Phase 1b data for TRV130 published in the journal Pain

Trevena, Inc., a clinical stage biopharmaceutical company and the leader in the discovery of G protein coupled receptor (GPCR) biased ligands, today announced the publication of its Phase 1b data for TRV130 in the journal Pain. [More]
Trevena reports positive results from TRV734 Phase 1 trial for treating acute/chronic pain

Trevena reports positive results from TRV734 Phase 1 trial for treating acute/chronic pain

Trevena, Inc. (NASDAQ:TRVN) today announced positive results from its Phase 1 trial of TRV734, which Trevena is developing with the goal of providing improved analgesia while avoiding gastrointestinal and respiratory side effects typically associated with opioids. [More]

Virtual reality can be effective adjunct for chronic and acute pain conditions

Chronic pain due to disease or injury is common, and even prescription pain medications cannot provide acceptable pain relief for many individuals. [More]

FDA issues Complete Response Letter to QRxPharma regarding Moxduo NDA

QRxPharma Limited announced today the United States Food and Drug Administration has issued a Complete Response Letter regarding the Moxduo New Drug Application for the treatment of moderate to severe acute pain. [More]
EU-funded project finds way to improve patients' pain treatment after surgery

EU-funded project finds way to improve patients' pain treatment after surgery

Millions of people undergo surgery each year. Many of them suffer from moderate to severe pain afterwards. This post-operative pain may impede recovery or even lead on into chronic pain. Now, the EU-funded project PAIN-OUT, completed in 2012, may have found a way to improve patients' pain treatment after surgery. [More]

Researchers analyze patient satisfaction with pain treatment after surgery

An international research group with members from the University of Basel, several EU countries, Israel and the USA, analyzed patient satisfaction with pain treatment after surgery. [More]
MEDNAX acquires Fredericksburg Anesthesia Associates

MEDNAX acquires Fredericksburg Anesthesia Associates

MEDNAX, Inc., today announced the acquisition of Fredericksburg Anesthesia Associates, Inc., a private practice physician group based in Fredericksburg, Va. The practice will become part of MEDNAX's American Anesthesiology division and is the third Virginia-based anesthesia practice to join the division. [More]
POZEN reports total revenue of $4.7 million for fourth quarter 2013

POZEN reports total revenue of $4.7 million for fourth quarter 2013

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the fourth quarter and year ended December 31, 2013. [More]
AcelRx Pharmaceuticals announces financial results for fourth quarter and full year 2013

AcelRx Pharmaceuticals announces financial results for fourth quarter and full year 2013

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and twelve months ended December 31, 2013. [More]
Study reveals spinal manipulation therapy reduces severity of pain in many patients

Study reveals spinal manipulation therapy reduces severity of pain in many patients

The lessening of pain sensitivity achieved with spinal manipulation therapy (SMT) occurs as a result of the treatment and not as much from a placebo effect caused by the expectation of receiving SMT, according to a study published in The Journal of Pain. [More]
FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved TIVORBEX™ (indomethacin) capsules, a nonsteroidal anti-inflammatory drug (NSAID), at 20 mg and 40 mg doses for the treatment of mild to moderate acute pain in adults. [More]
Mallinckrodt's subsidiary to acquire all outstanding shares of Cadence Pharmaceuticals

Mallinckrodt's subsidiary to acquire all outstanding shares of Cadence Pharmaceuticals

Mallinckrodt plc, a leading global specialty pharmaceuticals company, and Cadence Pharmaceuticals, Inc. today announced that they have entered into a definitive agreement under which a subsidiary of Mallinckrodt plc will commence a tender offer to acquire all outstanding shares of Cadence Pharmaceuticals, Inc. for $14.00 per share in cash or approximately $1.3 billion on a fully diluted basis, which represents a 32% premium to the trailing 30-trading-day volume weighted average price (VWAP) of $10.62 per share for Cadence Pharmaceuticals, Inc. [More]
Researchers shed new light on pain associated with bacterial infections

Researchers shed new light on pain associated with bacterial infections

Components in the outer wall of bacteria directly activate pain sensors, triggering immediate pain and inflammatory responses. This finding by a multinational team of researchers led by Professor Karel Talavera (KU Leuven, Belgium) and Professor Félix Viana (Institute of Neuroscience, Spain) sheds new light on pain associated with bacterial infections and reveals a new target for drugs designed to treat them. [More]